Clinical research
In its third installment of the Good Pharma Scorecard, Roche and Novo Nordisk scored perfect marks in overall trial transparency, while Johnson & Johnson slipped from the high spot on the previous ranking.
Tau Morphomer™ is the focus of a partnership with Eli Lilly and Company
Polyphor announced that it has decided to close the Phase III PRISM MDR and UDR studies of murapavadin intravenous for hospital-acquired and ventilator-associated bacterial pneumonia which have been put on a voluntary temporary hold on May 9th, 2019.
Pharma and biotech companies from across the globe provide updates on their pipelines and corporate strategy.
With the latest major Phase 3 failure of Biogen and Eisai’s beta-amyloid-targeting antibody drug aducanumab, researchers are increasingly turning to other drug targets for Alzheimer’s disease.
There’s been quite a few small and mid-sized deals announced today. Let’s take a look at four of them.
More than 600 employees will lose their jobs as the companies reshape their corporate strategies.
A disproportionate number of ALS patients on the investigational drug developed pneumonia.
The asset, LYT-100, is an oral compound that has shown anti-fibrotic and anti-inflammatory properties.
Four years ago, Takeda Pharmaceutical Company and The Center for iPS Cell Research and Application (CiRA) at Kyoto University established a 10-year joint research program. Today, the organizations made an announcement.
PRESS RELEASES